Subgroup Analysis of the Benefit of Avasopasem Manganese on the Incidence, Severity, Duration and Onset of Severe Oral Mucositis in ROMAN Phase 3 Trial

IMRT plus cisplatin is established treatment for LAHNC, but ∼70% of patients develop severe oral mucositis (SOM; WHO grade 3 or 4), limiting their ability to eat solids (gr 3) or liquids (gr 4), and often requiring feeding tube nutrition. Radiotherapy (RT)-induced bursts of superoxide initiate SOM (Sonis 2004). Avasopasem (AVA) is an investigational small molecule selective dismutase mimetic converting superoxide to hydrogen peroxide, which may protect normal cells from, and potentially sensitize cancer cells to, RT (Anderson 2019, Sishc 2021).

Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: G.V. Walker, C.M. Lee, J.R. Kelley, N.E. Dunlap, V. Bar-Ad, D.A. Miller, V. King, A. Peddada, D. Ciuba, F. Vincent, B.C. Muzyka, A.L. Gillespie-Twardy, S. Sonis, J. Holmlund, D. Saunders, R. Beardsley, C.M. Anderson Tags: 166 Source Type: research